9 completed, 2 recruiting, 2 terminated, 1 withdrawn. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 9, Recruiting 2, Terminated 2, Withdrawn 1 |
Follow Angioedema: new trials by email Literature Review of Angioedema trials Research Report on Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | KalVista Pharmaceuticals, Ltd. | 100 | 2026-08-17 | 2026-09-17 |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema | Phase 4 | Completed | CSL Behring | 18 | 2025-04-28 | 2026-07-23 |
| A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE) | Phase 4 | Completed | Nang Kuang Pharmaceutical Co., Ltd. | 5 | 2024-09-27 | 2025-12-18 |
| Lanadelumab in Long-term Prophylaxis of Acquired Angioedema Lanadelumab 300 mg - Angioedema | Phase 4 | Recruiting | Bernstein Clinical Research Center | 5 | 2024-06-01 | 2025-02-25 |
| Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) Ruconest - Hereditary Angioedema | Phase 4 | Completed | Bernstein Clinical Research Center | 5 | 2018-08-14 | 2024-11-15 |
| A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions C1-esterase inhibitor [recombinant] (C1-INH-R) - CVI - Common Variable Immunodeficiency | Phase 4 | Completed | IMMUNOe Research Centers | 20 | 2018-06-13 | 2021-02-15 |
| Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Omalizumab, Placebos - Idiopathic Angioedema | Phase 4 | Completed | University of Wisconsin, Madison | 12 | 2017-03-30 | 2022-11-01 |
| C1-inhibitor in Allergic ASThma Patients C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | T. van der Poll | 37 | 2016-11-16 | 2020-06-24 |
| A Call Center During HAE Attacks (SOS HAE) phone to the call center - Hereditary Angioedema | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 200 | 2013-03-01 | 2016-12-13 |
| Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Icatibant - Hereditary Angioedema | Phase 4 | Completed | Massachusetts General Hospital | 19 | 2011-12-01 | 2016-10-18 |
| Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection - Hereditary Angioedema Types I and II | Phase 4 | Completed | CSL Behring | 46 | 2011-11-01 | 2017-02-06 |
| Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema icatibant, Placebo - ACE Inhibitor-associated Angioedema | Phase 4 | Terminated | Vanderbilt University Medical Center | 33 | 2011-08-01 | 2017-02-17 |
| C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation C-1-esterase, placebo - Hereditary Angioedema | Phase 4 | Withdrawn | Penn State University | 2010-07-01 | 2012-11-30 | |
| A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE C1 inhibitor (human) [C1 INH] - Hereditary Angioedema | Phase 4 | Completed | Shire | 20 | 2009-08-31 | 2021-06-23 |
Angioedemas, Hereditary (10) · Asthma (1) · Common Variable Immunodeficiency (1) · Drug-Related Side Effects and Adverse Reactions (1) · Genetic Diseases, Inborn (1) · Hereditary Angioedema Types I and II (1) · Rare Diseases (1)
Cardiovascular Diseases (14) · Hypersensitivity (14) · Hypersensitivity, Immediate (14) · Immune System Diseases (14) · Skin Diseases (14) · Skin Diseases, Vascular (14) · Skin and Connective Tissue Diseases (14) · Urticaria (14) · Vascular Diseases (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Hereditary Complement Deficiency Diseases (10) · Immunologic Deficiency Syndromes (10) · Primary Immunodeficiency Diseases (10) · Genetic Diseases, Inborn (9)
Complement C1 Inhibitor Protein (4) · icatibant (3) · SERPING1 protein, human (2) · Anti-Bacterial Agents (1) · Ciprofloxacin (1) · Complement C1 (1) · Injections (1) · Methods (1) · Metronidazole (1) · Omalizumab (1) · Sodium Chloride (1) · Vancomycin (1) · Water (1) · conestat alfa (1) · lanadelumab (1)
Bernstein Clinical Research Center (2) · CSL Behring (2) · Assistance Publique - Hôpitaux de Paris (1) · IMMUNOe Research Centers (1) · KalVista Pharmaceuticals, Ltd. (1) · Massachusetts General Hospital (1) · Nang Kuang Pharmaceutical Co., Ltd. (1) · Penn State University (1) · Shire (1) · T. van der Poll (1) · University of Wisconsin, Madison (1) · Vanderbilt University Medical Center (1)
United States (9) · Bulgaria (1) · Canada (1) · France (1) · Germany (1) · Hungary (1) · Netherlands (1) · Poland (1) · Romania (1) · Taiwan (1)
Jonathan Bernstein, MD (2) · Aleena Banerji, M.D. (1) · Isaac Melamed, MD (1) · Michael Lunn, DO (1) · Mikhail Rojavin (1) · Nancy J. Brown, MD (1) · Ravi Viswanathan, MD (1) · Sameer Mathur, MD/PhD (1)
PMID 27140403, PMID 27788880, PMID 29503044, PMID 31109849, PMID 33737935, PMID 34303860, PMID 35914662